Furthermore, overexpression of the PI3K/AKT/mTOR pathway was related to acquired resistance to gemtuzumab ozogamicin in acute myelocytic leukemia cells, and PI3K/AKT/mTOR inhibitors could lead to re-sensitization of the resistant cells [42]. The gene discussed is MTOR; the disease is acute myeloid leukemia.